TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Esperion
Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease

HLS Therapeutics received Health Canada approval to market NILEMDO® for reducing LDL-Cholesterol in Canadians at risk of cardiovascular disease, with commercial launch expected in Q2 2026.

Insights
MSpI   neutral

Mentioned as a partner of zerohash with no specific positive or negative context


ESPR   positive

Achieved regulatory approval in Canada, expanding market access for their cholesterol-lowering medication